SCHEMBL5540650

SCHEMBL5540650

Cc1nc2c(C)c(C)ccc2o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 1/20 0.38
KDM4E B2RXH2 3/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
STAT1 P42224 1/20 0.32
TSHR P16473 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2A6 P11509 1/20 0.31
POLB P06746 1/20 0.30
CBFB Q13951 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12930245 0.84 ELANE (0.45) ELANEL3MBTL1GAAKDM4EMAPT
SCHEMBL11750336 0.81 KDM4E (0.36) ELANEKDM4EMAPTMAPK1ALDH1A1
SCHEMBL30648052 0.79 ELANE (0.37) ELANEL3MBTL1GAAKDM4EMAPT
SCHEMBL10693336 0.79 ELANE (0.37) ELANEL3MBTL1GAAKDM4EMEN1
SCHEMBL5540643 0.79 ELANE (0.41) ELANEL3MBTL1GAAKDM4EMEN1
SCHEMBL29216348 0.79 ELANE (0.42) ELANEL3MBTL1GAAKDM4EMAPT
SCHEMBL9147142 0.79 KDM4E (0.35) ELANEKDM4EMAPTMAPK1
SCHEMBL6111601 0.79 MAPT (0.39) ELANEGAAKDM4EMAPTMAPK1
SCHEMBL17281458 0.77 ELANE (0.46) ELANEL3MBTL1GAAKDM4EMAPT
SCHEMBL28467656 0.76 ELANE (0.35) ELANEL3MBTL1GAAKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108558786-B Lubricating oil antifriction and antiwear additive and application thereof 武汉工程大学 2020-09-25 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ELANE 3771/4885L3MBTL1 1931/4885GAA 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.